Researchers test needle-free injector for malaria
This article was originally published in Clinica
Executive Summary
Bioject Medical Technologies has begun a US Phase I clinical trial of its needle-free injector for delivering a vaccine for malaria. Researchers at the US Army Medical Research Institute of Infectious Diseases are testing the Biojector 2000 jet injector as a means of delivering a DNA-based vaccine made by US gene-based pharmaceutical company Vical. There are currently no available vaccines for malaria. Pharmaceutical company Merck recently pulled out of a deal with Bioject (see Clinica No 849, p 13).
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.